biOasis Technologies makes siRNA breakthrough; InVivo Therapeutics Holdings details terms of IPO;

> Biomaterials company InVivo Therapeutics Holdings, focused on treating spinal cord injuries, announced the pricing and quantity of shares to be offered in its planned $14 million share offering. Release

> Central nervous system disease specialist biOasis Technologies says it has discovered a peptide vector that delivers siRNA into brain cells. Release

> The FDA approved Kinex Pharmaceuticals IND for an oral form of the cancer medication irinotecan. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.